EndALS (@FinishALS) profile picture

Momentum is building. Let’s #EndALS. Not an organization or charity. Just a Twitter account.

Joined May 2019
Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)Photo by EndALS (@FinishALS)
Such duplication of work in ALS Land. Such mixed messages. If u can only participate in 1 natural history study, please make it ALL ALS. It is well-designed & well-funded. NIH really stepped up. To get the mass of data in it will make a difference. all-als.org/
1
2
285
Insurance companies are evil. “Clinical benefit has not been established”….that’s literally why they performed a phase 3 study.
271
🚨 Warning: Websites and social media are full of claims with high promises for ALS/MND treatments. Read about ten red flags you should watch for from #ALSUntangled 🔗 ow.ly/mXBV50UVvAs 🛡️ Be protected from misinformation.
1
4
5
298
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases. I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known. People can contact me directly at my first name (as written in my profile) at octant.bio.
976
5,230
205
18,739
2,658,173
Some sad news to report: Austin Leclaire was a remarkable young man with Duchenne muscular dystrophy who raised awareness about his devastating disease, and as a patient advocate, played a pivotal role in spurring the development of the first medicines to treat it. Austin died on Feb. 1, according to an announcement from his family. He was 26. I didn’t know Austin well, but I first met him in 2012 at an event in Boston organized by his mother, Jennifer McNary, and other Duchenne advocates who were pushing Sarepta Therapeutics to speed up the development of eteplirsen, its first drug to treat Duchenne. I can’t recall any of the speeches made that night, but I have a vivid memory of Austin, then already in a wheelchair, and his younger brother Max, also born with Duchenne and bouncing around the room like a jitterbug, captivating the crowd. Eteplirsen was a controversial drug, even back then. But what those gathered that night hoped for — as they watched two brothers playing joyfully, waiting impatiently for the adults to stop talking — were new treatments that could end a terrible disease. The event concluded with McNary and the other advocates presenting Sarepta's then-CEO Chris Garabedian with an hourglass, because in their words, time was something boys with Duchenne couldn’t afford to lose. Austin was a champion for the Duchenne community. His advocacy work, his optimism, his self-described “raunchy comedy act” and participation in competitive sports — it all inspired people. He was deeply loved by his mom, who was so proud of the man he had become. “My wish for his legacy is what he would have wanted — for people to remember him loudly. He loved the spotlight and aspired to change the world,” McNary told me via email. “He was an amazing son, big brother, friend and much more. I want us all to remember his contributions to the world because he had every reason to wallow and be selfish but he never complained and did everything he could to serve.” My condolences to Jenn, Max, and their extended family at this difficult time. Austin had a huge impact on everyone he met and he will be remembered fondly.
7
15
3
197
18,256
Treatment with the therapy was also associated with a roughly 50% slowing of respiratory declines. Review all findings here: bit.ly/4aAcLdr #ALS #AmyotrophicLateralSclerosis #ALSDisease #ALSTreatment #ALSResearch
4
4
292
Searching for something on X and the name that appears on the toolbar is someone that lost their ALS fight several years ago and I had to stop for a second. We only conversed on Twitter, but I could tell he was a great man. This disease just sucks.
1
1
13
732
EndALS retweeted
Replying to @ShorterLab
The study showcases a critical link between stress-induced TDP-43 nuclear condensation and its downstream effects on splicing and STMN2 levels. This underscores the molecular intricacies behind neurodegenerative processes, potentially highlighting novel therapeutic targets. For more in-depth biomedical insights, explore sciqst.com, an AI-driven platform to generate comprehensive biomedical reviews. #Medicine #Neuroscience #OpenAI Sciqst powered by OpenAI.
1
1
199
Living with ALS at 27: Young Canadian with ALS opens up about life after diagnosis that 'throws your future up in the air' ca.style.yahoo.com/living-wi… via @Yahoo
2
2
473
Excited for this. If you’d like to embed @ALSTDI’s ALS Trial Navigator this is now an option. Thank you to the Scott Morgan Foundation for doing so!
Breaking news! The ScottMorgan Foundation, @DrScottMorgan, partners with @ALSTDI to host the ALS Trial Navigator, a global first in personalized access to ALS/MND trials. Created by @ALSTDI, this revolutionary tool empowers patients to find the right clinical trials for them. #EndALS #ALSResearch #ALS #MND
7
20
940
#NewProfile #ALS #MND Unravelling the role of cell signalling in our molecular mechanistic understanding of amyotrophic lateral sclerosis/motor neuron disease ppu.mrc.ac.uk/research/princ… – at Dundee, Scotland
6
32
2,404